ClinicalTrials.gov
public full text
Public Domain
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart), of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset, subfoveal and/or juxtafoveal choroidal neovascularization.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery#877424
- PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization#1171838
- A Study Of Early Markers Of Choroidal Neovascularization#1140519
- A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration#1152517
- Evaluation of choroidal thickness and its associated factors among age-related macular degeneration patients#613796
Record · ID 980418
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive